Chemistry:Atypical antidepressant
An atypical antidepressant is any antidepressant medication that acts in a manner that is different from that of most other antidepressants. Atypical antidepressants include agomelatine, bupropion, iprindole, mianserin, mirtazapine, nefazodone, opipramol, tianeptine, and trazodone.[1][2][3] The agents vilazodone and vortioxetine are partly atypical. Typical antidepressants include the SSRIs, SNRIs, TCAs, and MAOIs, which act mainly by increasing the levels of the monoamine neurotransmitters serotonin and/or norepinephrine.[1][2][3] Among TCAs, trimipramine is an atypical agent in that it appears not to do this.[3] In August 2020, esketamine (JNJ-54135419) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression with the added indication for the short-term treatment of suicidal thoughts.[4]
Buprenorphine/samidorphan (ALKS-5461) is an antidepressant with a novel mechanism of action which was formerly under development and considered an atypical antidepressant.[5] They act faster than available antidepressants.[5]
See also
References
- ↑ 1.0 1.1 "Mechanism of action of antidepressant medications". J Clin Psychiatry 60 (Suppl 4): 4–11; discussion 12–3. 1999. PMID 10086478.
- ↑ 2.0 2.1 "Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action". J Clin Psychiatry 59 (Suppl 4): 5–14. 1998. PMID 9554316.
- ↑ 3.0 3.1 3.2 "Pharmacology of antidepressants". J Clin Psychopharmacol 17 (Suppl 1): 2S–18S. 1997. doi:10.1097/00004714-199704001-00002. PMID 9090573.
- ↑ "FDA Approves A Nasal Spray To Treat Patients Who Are Suicidal". NPR.org. 4 August 2020. https://www.npr.org/2020/08/04/899060885/fda-approves-a-nasal-spray-to-treat-patients-who-are-suicidal.
- ↑ 5.0 5.1 "Investigational drugs in recent clinical trials for treatment-resistant depression". Expert Rev Neurother 17 (6): 593–609. 2017. doi:10.1080/14737175.2017.1283217. PMID 28092469.
 |  |
